Head and Neck Cancer Research - Penn State Cancer Institute
Head and Neck Cancer Research
Research into head and neck cancer at Penn State Cancer Institute is conducted by the dedicated head and neck cancer team. See current clinical trials and members of that team here.
Clinical Trials
Effect of oral black raspberry administration on oral cell DNA adducts in smokers
The COVID-19 and Cancer Consortium (CCC19) Registry
NRG HN009- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Dysgeusia and Anosmia in Head and Neck Cancer Patients: Long Term Outcomes
A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of AAV2-hAQP1 Gene Therapy in Participants with Radiation-Induced Late Xerostomia (RIX)
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
ACR 3518: Phase I Safety Assessment of Hypofractionated Postoperative Radiotherapy (H-PORT) for Intermediate-Risk Head and Neck Cancer
Exploring Factors Associated with Understanding Among Head and Neck Surgery Patients
Head and Neck Cells: Tissue Repository
Disease Team Members
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
 |
Melissa | Boltz | DO | ||
 |
David | Goldenberg | MD | ||
 |
Neerav | Goyal | MD, MPH | ||
 |
Jessyka | Lighthall | MD | ||
 |
Mitchell | Machtay | MD | ||
 |
Brian | Saunders | MD |
Research into head and neck cancer at Penn State Cancer Institute is conducted by the dedicated head and neck cancer team. See current clinical trials and members of that team here.
Effect of oral black raspberry administration on oral cell DNA adducts in smokers
The COVID-19 and Cancer Consortium (CCC19) Registry
NRG HN009- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Dysgeusia and Anosmia in Head and Neck Cancer Patients: Long Term Outcomes
A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of AAV2-hAQP1 Gene Therapy in Participants with Radiation-Induced Late Xerostomia (RIX)
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
ACR 3518: Phase I Safety Assessment of Hypofractionated Postoperative Radiotherapy (H-PORT) for Intermediate-Risk Head and Neck Cancer
Exploring Factors Associated with Understanding Among Head and Neck Surgery Patients
Head and Neck Cells: Tissue Repository
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
|
Melissa | Boltz | DO | ||
|
David | Goldenberg | MD | ||
|
Neerav | Goyal | MD, MPH | ||
|
Jessyka | Lighthall | MD | ||
|
Mitchell | Machtay | MD | ||
|
Brian | Saunders | MD |